Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

New discovery points to potential drug targets for ASXL1-mutant chronic myelomonocytic leukemia

New research from Mayo Clinic's Center for Individualized Medicine finds that patients with ASXL1-mutant chronic myelomonocytic leukemia -; an uncommon type of cancer of the bone marrow -; have distinctive epigenetic changes that can activate harmful genes and cause the cancer to grow faster.

18 Mar 2022

Discovery may open novel avenues to prevent or treat hematological malignancies

Scientists at Yale Cancer Center have discovered new consequences of specific gene mutations that play a role in the development of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

17 Mar 2022

Zentalis contributes $1 million to SU2C Catalyst program for research into targeted cancer therapeutics

Stand Up To Cancer and Zentalis Pharmaceuticals, Inc. today announced that Zentalis will contribute $1 million to the SU2C Catalyst program to support research that investigates the use of certain small molecule inhibitors for treating a variety of cancer types.

15 Mar 2022

Tumor cells’ 'ferroaddiction' can be exploited to deliver powerful anticancer drugs

Researchers at the University of California, San Francisco, have discovered that cells carrying the most common mutation found in human cancer accumulate large amounts of ferrous iron and that this "ferroaddiction" can be exploited to specifically deliver powerful anticancer drugs without harming normal, healthy cells.

11 Mar 2022

Researchers examine how structural violence can set the stage for poorer leukemia outcomes

Black and Hispanic people with acute myeloid leukemia in greater Chicago were more likely to die from the disease than their non-Hispanic white counterparts, with a 59% and 25% greater risk, respectively, according to a new study led by University of Illinois Chicago researchers.

7 Mar 2022

Study provides insight into what causes therapy failure in patients with myelodysplastic syndromes

Researchers from The University of Texas MD Anderson Cancer Center discovered that treatment resistance in patients with myelodysplastic syndromes (MDS) is caused by two distinct classes of stem cells and identified possible therapeutic approaches that target these cells.

3 Mar 2022

Study reveals how the immune system can be triggered to attack cancer cells

New research from the University of East Anglia and Quadram Institute reveals how our immune system can be triggered to attack cancer cells.

1 Mar 2022

Study reveals how the immune system can be triggered to fight cancer cells

New research from the University of East Anglia and Quadram Institute reveals how our immune system can be triggered to attack cancer cells.

25 Feb 2022

HIV patient treated with blood stem cell transplant for leukemia achieves long-term remission

A patient living with HIV who received a blood stem cell transplant for high-risk acute myeloid leukemia has been free of the virus for 14 months after stopping HIV antiretroviral drug treatment, suggesting a cure, according to the Weill Cornell Medicine physician-scientists who performed the transplant and managed her care

21 Feb 2022

New mutation may define a high-risk subtype of pediatric acute myeloid leukemia

A new mutation was identified in 9 percent of relapsed cases of pediatric acute myeloid leukemia (AML) that may define a new subtype of the disease.

17 Feb 2022

New high-risk subtype of relapsed pediatric AML revealed

When acute myeloid leukemia (AML) relapses, it is more difficult to treat and outcomes are dismal. Scientists at St. Jude Children's Research Hospital have discovered a mutation in pediatric AML that physicians can use to identify high-risk patients and better guide treatment.

17 Feb 2022

Optical genome mapping holds potential to become an important component of leukemia diagnostics

Optical genome mapping involves the extraction of very long DNA molecules, for example routinely collected blood samples or bone marrow material from patients.

17 Feb 2022

Combating leukemia cells by disrupting their energy maintenance mechanism

Acute myeloid leukemia, which affects blood and bone marrow cells, is a particularly dangerous form of cancer. More than half of patients under the age of 60 die.

17 Feb 2022

A third known case of HIV remission involving stem cell transplant documented

A woman with HIV who received a cord blood stem cell transplant to treat acute myeloid leukemia has had no detectable levels of HIV for 14 months despite cessation of antiretroviral therapy (ART), according to a presentation at today's Conference on Retroviruses and Opportunistic Infections (CROI).

15 Feb 2022

Molecular cage helps researchers to get atomic-level details of key cancer protein

Acute myeloid leukemia (AML), the American Cancer Institute estimates, will affect more than 20,000 Americans this year and kill more than 11,000 of them.

11 Feb 2022

New method decodes the role of DDX41 protein in preventing double-strand breaks in DNA

There are many different ways in which the genetic material DNA can be damaged, resulting in the development of diseases such as cancer. Certain forms of DNA damage are associated with so-called R-loops.

8 Feb 2022

Researchers compare survival rates of AML patients treated with two forms of transplantation methods

Acute myeloid leukemia (AML) is a common type of blood cancer that has a relatively low survival rate. It is particularly deadly for patients suffering from refractory and relapsed AML (R/R AML), meaning their cancer has stopped responding to treatment and has returned after a period of remission.

5 Jan 2022

$Study finds new treatment option for patients with relapsed or refractory peripheral T-cell lymphoma$

Acute Myeloid Leukemia News and Research

Further Reading

New discovery points to potential drug targets for ASXL1-mutant chronic myelomonocytic leukemia

Discovery may open novel avenues to prevent or treat hematological malignancies

Zentalis contributes $1 million to SU2C Catalyst program for research into targeted cancer therapeutics

Tumor cells’ 'ferroaddiction' can be exploited to deliver powerful anticancer drugs

Researchers examine how structural violence can set the stage for poorer leukemia outcomes

Study provides insight into what causes therapy failure in patients with myelodysplastic syndromes

Study reveals how the immune system can be triggered to attack cancer cells

Study reveals how the immune system can be triggered to fight cancer cells

HIV patient treated with blood stem cell transplant for leukemia achieves long-term remission

New mutation may define a high-risk subtype of pediatric acute myeloid leukemia

New high-risk subtype of relapsed pediatric AML revealed

Optical genome mapping holds potential to become an important component of leukemia diagnostics

Combating leukemia cells by disrupting their energy maintenance mechanism

A third known case of HIV remission involving stem cell transplant documented

Molecular cage helps researchers to get atomic-level details of key cancer protein

New method decodes the role of DDX41 protein in preventing double-strand breaks in DNA

Researchers compare survival rates of AML patients treated with two forms of transplantation methods

Study finds new treatment option for patients with relapsed or refractory peripheral T-cell lymphoma

Novel immunotherapy shows promise for children, young adults with recurrent AML

Statistical models predict outcomes for patients receiving non-intensive AML therapy

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News